Exodus Point Capital Management, LP Gemini Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.31 - $2.01 $67,830 - $104,075	51,779 New	51,779 $85,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $53,790 - $103,016	-16,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $272,758 - $605,075	-43,158 Reduced 72.59%	16,300 $105,000
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $673,064 - $1.07 Million	59,458 New	59,458 $806,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.